Biotechnology company Chai Discovery has received nearly $30 million in investment from Thrive Capital and OpenAI within six months of its founding. The company focuses on the application of biotechnology in drug development, developing innovative technologies that can predict biochemical molecular structures and reprogram molecular interactions, aiming to transform biology into 'engineering.' Chai Discovery's goal is to accelerate and optimize the drug development process by enhancing drug molecule design through technologies such as artificial intelligence and machine learning.